Kosidina

Ethinylestradiol/Gestodene, the active ingredients in Kosidina, are a combined oral contraceptive presented as a tablet for oral use. They prevent pregnancy in women of reproductive age by suppressing ovulation and altering cervical mucus.

GNH USA supplies Kosidina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kosidina, a combined oral contraceptive, is used within the hormonal contraceptive pathway to prevent pregnancy.

- Contraception: Prevents unintended pregnancy by inhibiting ovulation and fertilization. - Menstrual cycle regulation: Provides regular withdrawal bleeding and reduces menstrual irregularities. - Acne improvement: May lessen acne associated with hormonal fluctuations.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Breast tenderness: temporary swelling or soreness. - Headache: occasional mild to moderate pain. - Spotting: irregular light bleeding between periods. - Mood changes: slight fluctuations in mood. - Weight gain: modest increase in body weight.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Pulmonary embolism: clot migration to lung arteries. - Stroke: interruption of cerebral blood flow. - Myocardial infarction: heart attack risk. - Severe allergic reaction: rash, swelling, breathing difficulty. - Liver tumor: rare hepatic neoplasm.

Before prescribing Kosidina, clinicians should evaluate individual risk factors and counsel patients on safe use. - Assess medical history: screen for thromboembolic or cardiovascular disease. - Avoid smoking: especially >15 cigarettes/day in women over 35 years. - Monitor blood pressure: hypertension may increase clot risk. - Review concomitant drugs: enzyme inducers can lower effectiveness. - Confirm non‑pregnancy: perform a pregnancy test before initiation. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Kosidina may interact with several medicines that alter its efficacy or safety.

Major Interactions (Avoid): - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce contraceptive effectiveness. - Combined estrogen therapy (e.g., hormone replacement): increase thrombotic risk. - Antifungal azoles (e.g., ketoconazole): may raise hormone levels, heightening side‑effect potential.

Moderate Interactions (Monitor Closely): - Antibiotics such as tetracycline or metronidazole: may slightly diminish contraceptive reliability. - St. John’s wort: herbal inducer that can lower plasma concentrations. - Diuretics: may affect blood pressure control when used together.